The COVID-19 pandemic situation has resulted in many restrictions around the world, still, the players manufacturing PEG 3350 products were able to manage their product stock. Further, governing bodies of respective nations made significant efforts to aid in the proper distribution and supple of healthcare goods. Government and private companies around the world were working together to issue advice for those undergoing constipation treatment during these unprecedented times of COVID-19 around the world. Several steps were taken to get their needed output for the product. Additionally, by increasing the material prices, the companies attempted in maintaining their overall revenue. Hence, companies in the PEG 3350 market are finding out their ways to deal with this pandemic situation.
With respect to the current scope of the report, McKesson Corporation (US) is the top player in the global PEG 3350 market due to its strong product offering and high preference for its products by customers. Bayer AG (Germany) is the second major player, followed by BASF SE (Germany), Merck KGaA (US), and Teva Pharmaceutical Industries Ltd. (Israel). Other key players contributing to the market growth include Lupin Pharmaceuticals, Inc. (India), Breckenridge Pharmaceutical, Inc. (US), Pendopharm (Canada), LGM Pharma (US), and Sisco Research Laboratories Pvt. Ltd. (India).
Threat of New Entrants
The threat of new entrants in the global PEG 3350 market is moderate. The global PEG 3350 market is steadily growing, hence attracting many new entrants who are looking to make a profit. However, the entry barriers are high due to strict government norms and regulations which decreases the threat of new entrants to some level. Companies aim to increase their market share and capture the market share which is mostly untouched by major players. Hence, the threat of new entrants in the global PEG 3350 market is moderate.
Bargaining Power of Suppliers
The bargaining power of suppliers in the global PEG 3350 market is high as there is an increase in demand for raw materials by pharmaceutical companies. However, the number of suppliers is also high in the market, which is slightly decreasing the bargaining power of suppliers, as switching cost is low. Additionally, the supply of raw materials is disrupted to some level due to the logistics issues that the world is facing currently, which in turn increases the bargaining power of suppliers.
Threat of Substitutes
The threat of substitutes in the PEG 3350 market is high. There are many substitutes for PEG 3350 such as magnesium citrate supplement and presence of natural alternatives. The doctors tend to prescribe the type of treatment that is suitable for the patient and also affordable.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global PEG 3350 market. Online pharmacies and offline pharmacies are the major buyers in the market. The bargaining power of the buyer can define how easily the buyer can get the products. Buyers in the global PEG 3350 market can choose from different companies. Most of the companies are offering the same kind of products so the switching cost for the buyer is relatively low.
Intensity of Rivalry
The degree of competition in the PEG 3350 market is high owing to the presence of a large number of prominent players. Low level of product differentiation among existing players increases the intensity of rivalry in the market. Polyethylene glycol 3350 companies are trying to develop economical and more effective medications to make the treatment more affordable and attractive. Additionally, the providers are also involved in innovating medicines for the different routes of administration. Such innovations might increase the level of product differentiation and will support the sales of the manufacturers.
